Outlook Therapeutics takes a major step forward in its plan to gain approval for wet AMD drug Lytenava; the first commercial FLIGHT procedures using the ViaLuxe Laser System are performed in Europe; and Oculus introduces a new AI-assisted tool designed to help clinicians evaluate MGD using meibography images. Learn more about your ad choices. Visit megaphone.fm/adchoices
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from Eyewire News: The Podcast
Tecnis PureSee IOL Fully Launched in the US
Study Examines Semaglutide and Wet AMD Risk
Oculis Announces Phase 3 Results for DME Eye Drops
Next-Generation FSYX Goggles Approved for Glaucoma
Get summaries like this every morning.
Free AI-powered recaps of Eyewire News: The Podcast and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.